Suppression of Choroidal Neovascularization by Dendritic Cell Vaccination Targeting VEGFR2

To investigate whether the induction of cellular immunity against vascular endothelial growth factor receptor (VEGFR) 2 inhibits the development of choroidal neovascularization (CNV). H-2Db-restricted peptide corresponding to amino acids 400 to 408 of VEGFR2 was used as an epitope peptide. Dendritic...

Full description

Saved in:
Bibliographic Details
Published in:Investigative ophthalmology & visual science 2007-10, Vol.48 (10), p.4795-4801
Main Authors: Mochimaru, Hiroshi, Nagai, Norihiro, Hasegawa, Go, Kudo-Saito, Chie, Yaguchi, Tomonori, Usui, Yoshihiko, Kurihara, Toshihide, Koto, Takashi, Satofuka, Shingo, Shinoda, Hajime, Ozawa, Yoko, Tsubota, Kazuo, Kawakami, Yutaka, Ishida, Susumu
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes - immunology
Choroidal Neovascularization - metabolism
Choroidal Neovascularization - prevention & control
Cytotoxicity, Immunologic
Dendritic Cells - immunology
Disease Models, Animal
Dose-Response Relationship, Drug
Enzyme-Linked Immunosorbent Assay
Epitopes - immunology
Eye and associated structures. Visual pathways and centers. Vision
Flow Cytometry
Fundamental and applied biological sciences. Psychology
Immunity, Cellular
Interferon-gamma - metabolism
Lymphocyte Depletion
Male
Mice
Mice, Inbred C57BL
Oligopeptides - immunology
T-Lymphocytes, Cytotoxic - immunology
Tumor Necrosis Factor-alpha - metabolism
Vaccination
Vaccines, Subunit - administration & dosage
Vascular Endothelial Growth Factor Receptor-2 - immunology
Vertebrates: nervous system and sense organs
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate whether the induction of cellular immunity against vascular endothelial growth factor receptor (VEGFR) 2 inhibits the development of choroidal neovascularization (CNV). H-2Db-restricted peptide corresponding to amino acids 400 to 408 of VEGFR2 was used as an epitope peptide. Dendritic cells (DCs) were harvested from bone marrow progenitors of C57BL/6 mice. Six-week-old C57BL/6 mice received subcutaneous injections of the epitope peptide-pulsed mature DCs three times at 6-day intervals. After the third immunization, laser photocoagulation was performed to induce CNV. One week after photocoagulation, mice were killed to harvest the choroid and splenocytes. CNV volume was evaluated by volumetric measurements. To confirm the specific immunogenicity of the epitope peptides in C57BL/6 mice, CD8 T cells isolated from harvested splenocytes were restimulated to measure interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha production through enzyme-linked immunospot assay and ELISA. To determine the T-cell subset responsible for the immunotherapy, mice were intraperitoneally injected with an anti-CD4 or anti-CD8 depletion antibody. CNV volume was significantly lower in mice immunized with the VEGFR2 epitope peptide than in those not immunized or immunized with a control peptide gp70. Cytokine assays showed the peptide-specific production of IFN-gamma and TNF-alpha from the CD8 T cells in a dose-dependent manner. In vivo depletion of CD8, but not CD4, T cells significantly reversed the suppressive effect of the VEGFR2 peptide-pulsed DC vaccination on CNV to the level observed in nonimmunized or gp70-immunized animals. These results indicate that the VEGFR2 peptide-specific induction of cellular immunity inhibits CNV through the cytotoxicity of CD8 T cells. Results of the present study suggested the possibility of DC vaccination targeting VEGFR2 as a novel therapeutic strategy for CNV.
ISSN:0146-0404
1552-5783
1552-5783
DOI:10.1167/iovs.07-0425